全文获取类型
收费全文 | 3217篇 |
免费 | 176篇 |
国内免费 | 15篇 |
专业分类
耳鼻咽喉 | 32篇 |
儿科学 | 39篇 |
妇产科学 | 22篇 |
基础医学 | 445篇 |
口腔科学 | 37篇 |
临床医学 | 241篇 |
内科学 | 675篇 |
皮肤病学 | 51篇 |
神经病学 | 530篇 |
特种医学 | 172篇 |
外科学 | 541篇 |
综合类 | 22篇 |
预防医学 | 133篇 |
眼科学 | 95篇 |
药学 | 215篇 |
中国医学 | 10篇 |
肿瘤学 | 148篇 |
出版年
2023年 | 17篇 |
2022年 | 24篇 |
2021年 | 84篇 |
2020年 | 56篇 |
2019年 | 64篇 |
2018年 | 70篇 |
2017年 | 51篇 |
2016年 | 84篇 |
2015年 | 97篇 |
2014年 | 130篇 |
2013年 | 167篇 |
2012年 | 224篇 |
2011年 | 229篇 |
2010年 | 137篇 |
2009年 | 137篇 |
2008年 | 200篇 |
2007年 | 239篇 |
2006年 | 204篇 |
2005年 | 217篇 |
2004年 | 180篇 |
2003年 | 174篇 |
2002年 | 176篇 |
2001年 | 34篇 |
2000年 | 23篇 |
1999年 | 22篇 |
1998年 | 44篇 |
1997年 | 34篇 |
1996年 | 28篇 |
1995年 | 23篇 |
1994年 | 22篇 |
1993年 | 15篇 |
1992年 | 9篇 |
1991年 | 9篇 |
1990年 | 7篇 |
1989年 | 8篇 |
1988年 | 12篇 |
1987年 | 11篇 |
1986年 | 5篇 |
1985年 | 7篇 |
1984年 | 8篇 |
1983年 | 8篇 |
1982年 | 8篇 |
1981年 | 11篇 |
1978年 | 5篇 |
1976年 | 5篇 |
1960年 | 4篇 |
1938年 | 4篇 |
1925年 | 5篇 |
1921年 | 4篇 |
1900年 | 3篇 |
排序方式: 共有3408条查询结果,搜索用时 15 毫秒
61.
62.
Richter CM Godes M Wagner C Maser-Gluth C Herzfeld S Dorn M Priem F Slowinski T Bauer C Schneider W Neumayer HH Kurtz A Hocher B 《Journal of hypertension》2004,22(1):191-198
BACKGROUND: It has been shown that the macula densa participates in the regulation of increased renin expression in two-kidney one-clip (2K1C) renovascular hypertension. Prostaglandins might be one of the mediators of macula densa function, because the cyclooxygenase-2 (COX-2), one of the rate-limiting enzymes of the prostaglandin pathway, is upregulated in 2K1C renovascular hypertensive rats. We tested the effect of chronic COX-2 inhibition on blood pressure, urinary aldosterone excretion and kidney morphology, as well as kidney function. METHODS: Four groups were established: two groups of 2K1C renovascular hypertensive rats treated with the specific COX-2 inhibitor Celecoxib (cele) (15 mg/kg per day) or placebo immediately after operation, and two sham-operated control groups fed with Celecoxib or placebo. RESULTS: Long-term COX-2 inhibition in 2K1C renovascular hypertensive rats did not alter blood pressure at any point of time. Urinary aldosterone excretion was elevated by clipping the renal artery (2K1C, 8.1 +/- 1.9, versus controls, 3.6 +/- 0.5 ng/24 h; P = 0.05) but was not influenced by treatment with Celecoxib. Also, Celecoxib treatment did not alter glomerular filtration rate (GFR), serum sodium, serum creatinine, serum urea or proteinuria in 2K1C renovascular hypertensive rats. Interstitial fibrosis of the left clipped kidney was markedly reduced (2K1C, 6.19 +/- 0.83% versus 2K1C + cele 3.00 +/- 0.68% of total area; P = 0.012), whereas the interstitial fibrosis of the non-clipped kidney or the glomerulosclerosis of both kidneys were not affected by Celecoxib treatment. CONCLUSIONS: Celecoxib reduces the interstitial fibrosis of the clipped kidney. Blood pressure, urinary aldosterone excretion or whole kidney function were not affected in renal hypertensive rats. 相似文献
63.
64.
Sujata Vaidyanathan Michael Bartlett Hans Armin Dieterich Ching‐Ming Yeh Ana Antunes Dan Howard William P. Dole 《Cardiovascular therapeutics》2008,26(4):238-246
This study investigated the pharmacokinetics, safety, and tolerability of aliskiren administered alone or in combination with either the loop diuretic furosemide or an oral extended‐release formulation of isosorbide‐5‐mononitrate (ISMN). In separate studies, 22 healthy subjects (ages 18–45 years) received either ISMN 40 mg or furosemide 20 mg once‐daily for 3 days followed by a 3‐day washout. Subjects then received aliskiren 300 mg once‐daily for 7 days followed by combination therapy for 3 days. Pharmacokinetic assessments were taken at regular intervals over 24 h after dosing on the last day of each treatment period. At steady state, aliskiren AUCτ was decreased by 7% (geometric mean ratio [90% CI], 0.93 [0.84, 1.04]), and Cmax by 20% (0.80 [0.65, 0.97]) with furosemide coadministration compared with aliskiren administration alone. Aliskiren coadministration reduced furosemide AUCτ by 28% (0.72 [0.64, 0.81]) and Cmax by 49% (0.51 [0.39, 0.66]) compared with furosemide alone. Coadministration of aliskiren and ISMN was associated with only minor changes in the pharmacokinetic parameters of aliskiren (AUCτ 1.03 [0.90, 1.18]; Cmax 0.94 [0.69, 1.29]) and ISMN (AUCτ 0.88 [0.71, 1.10]; Cmax 0.94 [0.79, 1.13]). Headache and dizziness were the most common adverse events in both studies; dizziness and BP values below normal (SBP <90 and/or DBP <50 mmHg) were more frequent with aliskiren and ISMN coadministration than with either agent alone. Coadministration of aliskiren and ISMN had no clinically relevant effect on either aliskiren or ISMN pharmacokinetics. In conclusion, coadministration of aliskiren and furosemide reduced furosemide exposure and had a minor effect on aliskiren pharmacokinetics. The clinical significance of reduced systemic exposure to furosemide during coadministration of aliskiren is uncertain. 相似文献
65.
Recent technological advances in CT imaging have revolutionized non-invasive imaging of the central airways. It is now possible to image the entire central airways in a few seconds and to create elegant three-dimensional reconstructions of the airways in a few minutes. The fast speed of CT scanning now allows for a dynamic assessment of the central airways, expanding the ability to non-invasively detect functional abnormalities such as tracheobronchomalacia. The purpose of this article is to familiarize clinicians with recent advances in airway imaging. A special emphasis is placed upon advanced CT reconstruction methods and their potential contributions to the evaluation of a variety of airway disorders. 相似文献
66.
67.
Ultrasound guidance for medical thoracoscopy: a novel approach 总被引:2,自引:0,他引:2
Hersh CP Feller-Kopman D Wahidi M Garland R Herth F Ernst A 《Respiration; international review of thoracic diseases》2003,70(3):299-301
BACKGROUND: Commonly, a pneumothorax is induced before medical thoracoscopy to facilitate safe entry into the pleural space. OBJECTIVE: Evaluate the use of transthoracic ultrasound to locate a safe entry site for trocar placement during medical thoracoscopy without induction of a preprocedure pneumothorax. METHOD: The study was designed as a prospective cohort study, performed in the setting of a tertiary care hospital with an active interventional pulmonology program. It included 20 consecutive patients referred for medical thoracoscopy. RESULTS: Ultrasound identified entry sites in all 20 patients. All sites were successfully used, despite the presence of adhesions in 3 patients. There were no complications. CONCLUSIONS: Ultrasound could safely and reliably identify entry sites for trocar placement during medical thoracoscopy, even in patients with pleural adhesions. The use of ultrasound may replace the practice of pneumothorax induction before medical thoracoscopy. 相似文献
68.
69.
Association between Lp-PLA2 and coronary artery disease: focus on its relationship with lipoproteins and markers of inflammation and hemostasis 总被引:7,自引:0,他引:7
Khuseyinova N Imhof A Rothenbacher D Trischler G Kuelb S Scharnagl H Maerz W Brenner H Koenig W 《Atherosclerosis》2005,182(1):181-188
Lipoprotein-associated phospholipase A2 (Lp-PLA2) generates pro-inflammatory molecules from oxidized LDL. We examined the association between Lp-PLA2 plasma concentrations and risk of stable coronary artery disease (CAD) in a large case-control study and further assessed the relationship between Lp-PLA2 and various lipid, inflammatory and hemostatic parameters. Lp-PLA2 concentrations were measured in 312 patients with CAD and in 479 age- and gender-matched blood donors. Various sensitive inflammatory and hemostatic markers and a complete lipoprotein profile were obtained. Lp-PLA2 concentrations were significantly higher in cases than in controls (296.1 ng/mL versus 266.0 ng/mL, p<0.0001). In multivariable logistic regression, the age- and gender-adjusted OR for the presence of CAD was 1.61 (95% CI, 1.07-2.44) if the top quartile of the Lp-PLA2 distribution was compared to the bottom quartile. Adjustment for traditional cardiovascular risk factors and statin use resulted in an OR of 2.04 (95% CI, 1.19-3.48). After additional controlling for vWF, the OR was slightly attenuated but still remained statistically significant (OR 1.91; 95% CI, 1.12-3.28). Thus, elevated Lp-PLA2 concentrations were associated with the presence of stable CAD, independent of various biochemical markers. Our results support the hypothesis that Lp-PLA2 may be a novel, independent risk marker for CAD. 相似文献
70.